Wen-Ming Wang,Hao Feng,Qian-Nan Jia et al.
Wen-Ming Wang et al.
Introduction: Inherited epidermolysis bullosa (EB) is a family of rare inherited dermatoses that result in mucocutaneous fragility and blister formation inducible by minor trauma. Clinically, EB mainly presents as increas...
An evaluation of bimekizumab for the treatment of hidradenitis suppurativa [0.03%]
评估bimekizumab治疗痤疮样皮病的效果
Tomasz Skrzypczak,Anna Skrzypczak,Łukasz Matusiak et al.
Tomasz Skrzypczak et al.
Introduction: Until recently, the biological treatment options for hidradenitis suppurativa (HS) were largely restricted to adalimumab and secukinumab. In 2024, bimekizumab, an IL-17A and IL-17F antibody was introduced to...
Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use [0.03%]
中重度银屑病靶向IL-23生物制剂的现实世界使用经验教训
Matteo Megna,Giuseppe Lauletta,Michela D&#x;Agostino et al.
Matteo Megna et al.
Introduction: Psoriasis is a chronic, systemic inflammatory disease with significant physical and psychosocial burden. Advances in understanding the pathogenesis of psoriasis, particularly the role of interleukin (IL)23/T...
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer [0.03%]
Datopotamab德鲁替康治疗非小细胞肺癌的评估分析
Neel Belani,Anjali Donnelly,Alexander Spira
Neel Belani
Introduction: Despite recent treatment breakthroughs, non-small cell lung cancer (NSCLC) remains the highest cause of cancer-related mortality. New therapies are urgently needed, particularly in patients without actionabl...
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration [0.03%]
评价AVT06与对照药阿柏西普在治疗新生血管性年龄相关性黄斑变性中的有效性和安全性的随机、双盲、平行分组、多中心临床试验
Hansjürgen Agostini,Kristine Baumane,Vilma Jūratė Balčiūnienė et al.
Hansjürgen Agostini et al.
Background: This study compared efficacy, pharmacokinetics (PK), immunogenicity, and safety between AVT06, proposed biosimilar to reference product (RP) aflibercept (Eylea®), in participants with neovascular age-related ...
Tight competition for the first line treatment of Hodgkin's lymphoma: a comprehensive review of practice-changing developments in recent years [0.03%]
经典松动霍奇金淋巴瘤一线治疗格局变迁：近年撼动实践的重要研究综述
Umut Yılmaz,Elif Birtaş Ateşoğlu,Burhan Ferhanoğlu
Umut Yılmaz
Introduction: There has been a giant leap forward in the management of Hodgkin's lymphoma (HL) over the past decade. Emergence of long-term data from large, randomized trials in early-stage disease (eHL) and incorporation...
Hideto Kameda,Reina Maezawa,Yasuto Minegishi et al.
Hideto Kameda et al.
An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma [0.03%]
评价denileukin diftitox治疗复发或难治性皮肤T细胞淋巴瘤的有效性和安全性
Amrita Goyal,Francine M Foss
Amrita Goyal
Introduction: Denileukin difitox (DD), a recombinant cytotoxic fusion protein composed of full-length human interleukin-2 (IL-2) conjugated to diphtheria toxin's A and B subunits, has shown activity in patients with relap...
"Full-naïve" patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis - a monocentric retrospective study [0.03%]
“满然无知”的病人：既往使用甲氨蝶呤、环孢素和阿维A对中重度银屑病一线生物制剂疗效的影响——单中心回顾性研究
Luca Mastorino,Paolo Dapavo,Orsola Crespi et al.
Luca Mastorino et al.
Background: The impact of traditional systemic drugs to treat psoriasis (ciclosporin, methotrexate, and acitretin) in a subsequent response to biologics, has not been adequately addressed in the literature. In clinical pr...
Hypoxic storage of red blood cells to improve transfusion outcomes in hematological malignancies [0.03%]
血液缺氧贮存可改善血液肿瘤输血效果
Håkon Reikvam,Tor Hervig
Håkon Reikvam